Commercial revenues of BioNTech by type 2023
In 2023, total commercial revenues of biotech company BioNTech SE stood at some 3.82 billion euros, of which 3.78 billion were due to the COVID-19 vaccine. This statistic illustrates the commercial revenues of BioNTech SE worldwide from 2017 to 2023, by type. On November 9th 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.